Medical News Home

Geron Corporation (Nasdaq:GERN) today announced that it has enrolled the first multiple myeloma patient in a clinical trial of its telomerase inhibitor drug, GRN163L, in combination with other treatments.

Hypoxia-induced injury occurs in the case of heart attack, stroke or other neurological or respiratory conditions which diminish the supply of oxygen to vital tissues and organs. Scientists know that most life forms are able to somehow suppress non-essential activity in order to survive oxygen deprivation, but they didn’t know why or how this metabolic slowdown occurred.

The Medicines Company (NASDAQ: MDCO) today announced one-year follow-up data from the landmark HORIZONS-AMI trial demonstrated that Angiomax_ (bivalirudin) significantly reduced cardiac-related death by 43 percent (p=0.005), improved overall survival by 31 percent (p=0.

New York Blood Center (NYBC), serving New York City, Long Island, Hudson Valley and New Jersey, is reporting slipping blood reserves due to increased September demand from hospitals and current economic strife. “Businesses are among our most dedicated supporters,” said NYBC President and CEO Dr. Robert Jones.

Bayer HealthCare LLC announced that the U.S. Food and Drug Administration (FDA) has approved routine prophylaxis with Kogenate(R) FS Antihemophilic Factor (Recombinant) to reduce the frequency of bleeding episodes and the risk of joint damage in patients aged 0-16 years with severe hemophilia A with no pre-existing joint damage.

The U.S. Food and Drug Administration has approved a new use for the blood product Kogenate FS to reduce the frequency of bleeding episodes and prevent joint damage in children with the most severe form of hemophilia. Hemophilia A is a rare, hereditary, bleeding disorder in which a protein needed to form blood clots, factor VIII, is missing or its level is reduced.

Cerus Corporation (NASDAQ: CERS) announced results from 10 studies on the INTERCEPT Blood System, presented this week at the AABB annual meeting in Montreal, Canada.

The U.S. Department of Defense has awarded The University of Texas Health Science Center at Houston a $9.2 million grant to conduct a multi-center clinical trial that could lead to an improved survival rate for trauma patients - both soldiers and civilians — who require massive blood transfusions. The university’s Center for Clinical and Translational Sciences (CCTS) is contracting with the U.

Interim study results show that once-daily Exjade® (deferasirox) reduces iron that can build up in key organs in patients who undergo repeated blood transfusions as part of their treatment for thalassaemia.

Omrix Biopharmaceuticals, Inc. (”Omrix”) (NASDAQ: OMRI), a fully-integrated biopharmaceutical company that develops and markets biosurgical and immunotherapy products, announced today interim results from its U.S.